#### 1 Climacteric status is associated with sexual dysfunction at the age of 46: a population-based study

- 2
- 3 Running title: Climacteric status and sexuality at mid-40s.
- 4

Authors: Susanna M. Savukoski, MD<sup>1,2</sup>, Pekka A. Pinola, MD<sup>1,2</sup>, Paula RO. Pesonen, MSc<sup>3</sup>, Katri S. Puukka,
 PhD<sup>2,4,5</sup>, Eila TJ. Suvanto, MD<sup>1,2</sup>, and Maarit J. Niinimäki, MD<sup>1,2</sup>

<sup>7</sup> <sup>1</sup>Department of Obstetrics and Gynaecology, PEDEGO Research Unit, Oulu University Hospital and

8 University of Oulu, 90029 OYS, Finland <sup>2</sup>Medical Research Centre Oulu, Oulu University Hospital and

9 University of Oulu, 90014 Oulu, Finland <sup>3</sup>Infrastructure for Population Studies, Faculty of Medicine,

10 University of Oulu, 90014 Oulu, Finland <sup>4</sup>NordLab Oulu, Oulu University Hospital, 90029 Oulu, Finland

<sup>5</sup>Department of Clinical Chemistry, University of Oulu, 90014 Oulu, Finland

12 FUNDING: Northern Finland Birth Cohort 1966 received financial support from University of Oulu Grant

no. 24000692, Oulu University Hospital Grant no. 24301140, ERDF European Regional Development Fund

14 Grant no. 539/2010 A31592. Pekka Pinola, Paula Pesonen, Katri Puukka, Eila Suvanto and Maarit Niinimäki

15 received no financial support for the research, authorship, and/or publication of this article. Susanna

16 Savukoski received a research grant from the Finnish Menopause Society, Juho Vainio Foundation, and

17 Finnish Medical Foundation.

18 CONFLICTS OF INTERESTS: The authors declare no potential conflicts of interest with respect to the

19 research, authorship, and/or publication of this article.

20 The manuscript or abstract have not been presented/published previously.

Corresponding author: Susanna Savukoski (<u>susanna.savukoski@oulu.fi</u>). Address Kajaanintie 50, 90220
 Oulu, Finland.

- 23 Reprint request: to Susanna Savukoski (susanna.savukoski@oulu.fi).
- 24 25

39

40

41

42

## 43 Abstract

44 **Objective:** Increasing age and menopausal transition increase the risk of sexual dysfunction. Sexual

45 dysfunction is common in women experiencing menopause before the age of 40, while evidence on sexual

46 function in women experiencing menopause in their mid-40s is scarce. We aimed to investigate sexual

47 function in 46-year-old women in relation to their menopausal status.

48 Methods: This study cross-sectionally evaluated sexual function of women in a prospective population-

based Northern Finland Birth Cohort 1966 (NFBC1966). A 46-year follow-up study of NFBC1966 included
 a broad questionnaire evaluating health, lifestyle, and life situation, as well as menstrual history and sexual

a broad questionnaire evaluating health, lifestyle, and life situation, as well as menstrual history and sexual
 function, and blood sampling analysis including follicle stimulating hormone (FSH) and free androgen index

52 (FAI). The participants were divided into two groups by their menopausal status, defined by FSH and

53 menstrual history. We performed logistic regression models in which parameters of sexual function were

54 dependent factors and climacteric status, self-reported health, FAI, relationship status, smoking, and

- education level were independent variables.
- **Results:** The study population included 2661 women. In regression models, more advanced climacteric

57 status was associated with higher frequency and difficulty level of low sexual desire and vaginal dryness

**58** (Odds ratios with 95% confidence intervals 2.80[2.12–3.71], 3.22[2.43–4.27], 3.83[2.82–5.20], 3.75[2.75–

59 5.12], respectively), lower frequency of sexual thoughts (1.34[1.02-1.75]), and higher frequency of problems

60 with intercourse (2.35[1.51–3.66]). Lower FAI and poorer health were associated with impaired sexual

61 function.

62 Conclusions: The current study suggests that women experiencing menopausal transition in their mid-40s63 are at risk of impaired sexual function.

Ethical Compliance: All procedures performed in studies involving human participants were in accordance
 with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and
 its later amendments or comparable ethical standards.

**Keywords**: female sexual function/ sexual dysfunction / menopausal transition / climacteric phase / early
 menopause

69 70

#### 91 Introduction

- 92 Menopausal transition is associated with impaired sexual function, independently of ageing <sup>1</sup>. Sex steroids --
- 93 estrogens and androgens -- play important roles in female sexual function, affecting the structure and
- 94 function of both the central nervous system and genitals<sup>2</sup>. During menopausal transition, estrogen levels first
- 95 fluctuate and then decline severely<sup>3</sup>, whereas androgen levels in women decrease continuously after the age
- 96 of 20<sup>-3</sup>. However, many non-hormonal factors, such as psychological, relationship-related, and cultural
- 97 factors, as well as the overall health of women and their partners, have been reported to affect sexual
- function in middle-aged women even more than sex hormone levels  $^{1,4}$ . Evidence suggests that the severity
- of menopause-related symptoms is inversely related to sexual function <sup>5</sup>. Hormone therapy (HT) may
   improve sexual function by relieving menopausal symptoms, though it does not appear to improve sexual
- improve sexual function by relieving menopausal symptoms, though it does not app
   function in postmenopausal women in general <sup>6</sup>.
- 102 The median age at menopause is 50 years <sup>7</sup>. Premature ovarian insufficiency (POI), defined as declining
- 103 ovarian function before the age of 40, has been associated with impaired sexual function in several studies <sup>8–</sup>
- 104 <sup>11</sup>. Not only hormonal but also psychosocial issues are important factors that mediate sexual function in
- women with POI  $^{12}$ . POI may have adverse psychological causes, as it increases the risk off depressive and
- anxiety symptoms as well as more negative self-image <sup>13</sup>. POI affects 1.1-3.7% of women, while 7.6-12% of women experience menopause between the ages of 40-44 (early menopause = EM)  $^{7,14}$ . Evidence on sexual
- function and wellbeing in women experiencing menopause at an early age but not fulfilling the criteria for
- 109 POI is scarce.
- 110 Smoking is associated with a higher risk of sexual dysfunction in women  $^{15,16}$ . Lower levels of free
- androgens have been associated with a higher prevalence of sexual dysfunction in premenopausal women<sup>17</sup>
- as well as lower libido in both postmenopausal and premenopausal women <sup>18,19</sup>. Some socioeconomic
- factors, such as lower level of education, have been associated with a higher prevalence of sexual problems,
- as well as poor health <sup>20</sup>. Sexual function is related to general health <sup>21</sup>.
- As very few studies have focused on sexual function in women facing menopausal transition in their 40s, this
- prospective birth-cohort study aimed to investigate the association between menopausal status and sexual
- 117 function in 46-year-old women. We used a wide range of parameters known to be associated with sexual
- 118 function in our analyses. The primary aim was to study whether menopausal status is associated with sexual
- 119 problems such as low sexual desire or vaginal dryness. Second, we aimed to describe which other parameters
- affected sexual function and the role of menopausal status among them.
- 121

# 122 Materials and methods

# 123 Study population and group division

- To create The NFBC1966, all pregnant women living in northern Finland with an estimated date of delivery within 1966 were recruited. Originally, the NFBC1966 contained 12,231 children, and it comprised 96.3% of all births in Northern Finland in 1966. The cohort members have been followed-up with comprehensive follow-up studies since the antenatal period. This study was based on the most recent follow-up study, performed at 46 years of age. In this follow-up study, 10,331 cohort members, of whom 5123 were women, were sent a postal questionnaire. Participants living in Oulu or the capital area were also invited to
- 130 participate in the clinical examination. <sup>22,23</sup>
- 131 The questionnaire evaluated life situation, health, lifestyle habits, and wellbeing. The questions related to this
- study concerned menstrual history, current use of medications (including contraceptive preparations), marital
- status, education level, smoking habits, and how the study participants estimated their current general health
- 134 (very good, good, moderate, poor, and very poor). Concerning sexuality, the participants were asked how
- frequently they suffered from 1) low sexual desire and 2) vaginal dryness, on a scale of 1-5 (1= not at all, 5= 126 years often) and how distructions they experience d these superscenes  $f_{1}$  =  $f_{1}$  =  $f_{1}$  =  $f_{1}$  =  $f_{1}$  =  $f_{1}$  =  $f_{2}$  =  $f_{1}$  =  $f_{2}$  =  $f_{1}$  =  $f_{2}$  =  $f_{1}$  =  $f_{2}$  =  $f_{2}$
- very often) and how distressing they experienced these symptoms on a scale of 1-7 (1=not at all, 7= very

- 137 distressing). They were also asked whether they currently had difficulties having sexual intercourse (no/yes/I
- have no partner), how often they thought about sex (never, once a month, once a week, 2-3 times a week,
- daily), and how often they had sexual intercourse or masturbation (never, once a month, once a week, 2-3
- times a week, daily).

141 The clinical examination included anthropometric measurements, such as weight and height, by which body

- mass index (BMI) was calculated. Blood samples was drawn from every participant to determinate several
   parameters, such as serum follicle stimulating hormone (FSH), testosterone, and sex hormone-binding
- 144 globuline (SHBG). Serum FSH levels were determined using an immunochemiluminometric method (Advia
- 145 Centaur XP, Siemens Healthcare Diagnostics, Tarrytown, NY, USA). Serum testosterone was assayed using
- an Agilent triple quadrupole 6410 LC/MS equipment (Agilent Technologies, Wilmington, DE, USA) and
- 147 SHBG using a chemiluminometric immunoassay (Immulite 2000, Siemens Healthcare, Llanberis, UK).
- 148 Therefore, SHBG values from age 31 were transformed to be comparable with the SHBG values analyzed at
- age 46 using a formula:  $0,7615 \times 0.13$  method 31 yr SHBG + 0,7088, and the results are reported according to this method. Free androgen index (FAI) was calculated using the formula: (testosterone/SHBG)  $*100^{24}$ .
- 151 Equals portionants of the 46 mon fallow we study when the line in the line in the line of the state of the
- Female participants of the 46-year follow-up study were divided into two groups based on their menstrual history and FSH levels: climacteric and preclimacteric women (Figure 1). The group "climacteric women"
- included women who were, according to Straw  $\pm 10$  criteria for reproductive stages<sup>25</sup>, in their late
- perimenopause or postmenopause, and the criteria were 1) FSH value > 25 IU/L and 2) amenorrhea  $\geq 60$
- 155 days before the study visit. The group "preclimacteric women" included premenopausal women and women
- in their early perimenopause, and the criteria were 1) FSH value  $\leq 25$  IU/L and having their last menstrual
- period < 60 days before the clinical examination. The women using systemic estrogen-containing hormone
- therapy (HT) were identified by the national medicine reimbursement register (if they had purchased HT
- during the one year prior to the 46-years study) and classified as "climacteric". The group division of women
- 160 who were hysterectomized or who had progestin-only treatment (peroral, intrauterine device, or subdermal
- implant) was classified according to their FSH level, regardless of their menstrual history. Women who used
- 162 combined estrogen-progestin hormonal contraceptive preparations (pills, rings, or patches) or tamoxifen
- were excluded from the study, as were women with missing or conflicting data.

# 164 Statistical methods

- 165 In comparing the background characteristics between the study groups, continuous variables with normal 166 distribution were analyzed with an independent samples *t*-test and variables with skewed distribution were
- analyzed using the Mann-Whitney *U* test. Categorical background variables were compared using the
- 168 Pearson's  $\chi^2$  test. Unadjusted and adjusted binary logistic regression models were used to investigate the
- association between climacteric status and sexuality-related variables. In the adjusted models, sexuality-
- related variables were dependent variables; climacteric status and other potential confounders—current
   smoking (yes/no), FAI, level of education (basic, secondary, tertiary), relationship status (living with a
- partner or not), and self-experienced general health (very good–good/moderate–very poor)—were
- independent variables. Confounders were chosen based on the findings of previous studies<sup>15–21</sup>. In
- subanalyses that included only climacteric women, we performed binary logistic regression models in which
- the use of HT, trouble with hot flashes, current smoking, FAI, level of education, relationship status, and
- general health were independent variables. A linear regression test was used to test multicollinearity,
- interpreting a variance inflation factor (VIF) >2.5 as multicollinearity between the variables. Statistical
- analyses were performed using IBM SPSS Statistics for Windows, version 26 (IBM Corp. Armonk, NY,
- USA). Fig. 1 was drawn using Microsoft PowerPoint software, version 2204 (Microsoft Corporation,
- 180 Redmond, Washington, USA) and Fig. 2 with GraphPad Prism version 8.0.1.244 (GraphPad Software, San
- 181 Diego, California, USA).
- 182
- 183 **Results**

- 184 The study groups included 359 climacteric and 2302 preclimacteric women (flow chart of the study
- population is shown in Fig.1). The background characteristics of this study population are shown in Table 1.
- 186 Climacteric women were more likely to be current smokers, slightly less educated, and experienced more
- severe hot flashes. Body mass index, self-reported general health, alcohol intake, FAI levels and marital
- 188 status did not differ between groups.
- 189 The distribution of answers to the questions concerning sexual function (sexual desire and vaginal dryness) is
- 190 presented in Table 2. Compared to preclimacteric women, climacteric women suffered more often from a
- low desire for sex as well as vaginal dryness and also reported having more trouble with these issues. They
  also thought less frequently about sex. Twenty-one (5.8%) climacteric and 130 (5.6%) preclimacteric women
- reported that they did not have a partner. Of the women who had a partner, climacteric women more often
- 194 had problems with intercourse than did the preclimacteric women.
- 195 In binary logistic regression models, adjusted for confounding variables, being climacteric vs. preclimacteric 196 was associated with all the investigated sexuality-related variables except frequency of
- 197 intercourse/masturbation: higher frequency and more trouble from low desire for sex and vaginal dryness
- 198 (odds ratios (ORs) with 95% confidence intervals (CIs): 2.80 [2.12–3.71], 3.22 [2.43–4.27], 3.83 [2.83–5.20]
- and 3.75 [2.75–5.12], respectively), thinking about sex less often (OR 1.34, 95% CI 1.02–1.75), and having
- more frequent problems with sexual intercourse (OR 2.35, 95% CI 1.51–3.66). Weaker self–reported health
   (moderate—very poor compared to good—very good) was associated with all the investigated variables:
- (inductate—very poor compared to good—very good) was associated with an the investigated variables:
   higher frequency and more trouble from low desire for sex and vaginal dryness (ORs with 95% CIs: 1.97)
- 203 (1.55-2.51), 1.96 (1.52-2.51), 1,83 (1.38-2.43) and 2.07 (1.56-2.75), respectively), thinking about sex less
- often (OR 1.44, 95% CI (1.18–1.77), having more problems with sexual intercourse (OR 2.52, 95% CI
- 1.71–3.70), and having sexual intercourse/masturbating less often (OR 1.44, 95% CI 1.18–1.74). In the
   models, lower FAI was associated with higher frequency of low sexual desire (OR 1.18, 95% CI 1.03–1.32)
- and vaginal dryness (OR 1.56, 95% CI 1.05–2.32), thinking about sex less often (OR 1.22, 95% CI 1.05–1.32)
- 1.35), more often having problems with sexual intercourse (OR 1.39, 95% CI 1.11–1.72), and having sexual
- intercourse/masturbating less often (OR 1.12, 95% CI 1.03–1.23). Living with a partner was associated with
   higher frequency and more trouble with low desire for sex and vaginal dryness (ORs with 95% CIs 1.93)
- [1.40-2.67], 2.44 [1.71-3.50], 1.72 [1.18-2.52] and 2.41 [1.58-3.70], respectively), having more frequent
- problems with sexual intercourse (OR 2.52 (1.71–3.70), but having sexual intercourse/masturbating more
- often (OR 2.02, 95% CI 1.64–2.48). The results of the binary logistic regression models are shown in Fig. 2
  and Table 3.
- 215 In the subanalyses, we investigated whether HT use and severity of hot flashes were associated with
- sexuality-related variables in climacteric women. In these analyses, having purchased HT during the last year
- 217 was associated with higher frequency of vaginal dryness (OR 2.50, 95% CI 1.22–5.13) and having more
- trouble with low desire for sex (2.05, 95% CI 1.03–4.08). Having more severe hot flashes was associated
- with higher frequency of low desire for sex (OR 6.62, 95% CI 3.78–11.60) and vaginal dryness (OR 8.17,
- 220 95% CI 4.38–15.20), as well as experiencing more difficulty as a result of low desire for sex (OR 8.06 95%
- 221 CI 4.54–14.31) and vaginal dryness (OR 9.59, 95% CI 5.03–18.25).
- In the regression models, all VIF-values were < 2.5; hence, multicollinearity between the independent</li>
   variables was not found.
- 224

# 225 Discussion

A more advanced climacteric status was associated with impaired sexual function at 46 years of age in the

- 227 current study. In the logistic regression models, being climacteric was independently associated with a higher
- risk of impairment in all sexuality-related variables except the frequency of sexual intercourse/masturbation.
- Additionally, lower FAI, living with a partner, and weaker self-reported health were associated with
- 230 impaired sexual function. In the subanalysis of climacteric women only, more disturbing hot flashes and
- having purchased HT during the last year were associated with impaired sexual function.

232 Sexual function and satisfaction in postmenopausal women play an important role in their general wellbeing.

- A study by Buczak-Stec et al. suggested that sexual satisfaction was positively associated with life
- satisfaction in adults over 40<sup>26</sup>. In addition, Woloski-Wruble et al. reported that in postmenopausal women,
- 235 sexual activity was positively correlated with sexual satisfaction and sexual satisfaction with life satisfaction
- <sup>27</sup>. Early age at menopause is a risk factor for sexual dysfunction through hormonal and psychological
- pathways, and it also exposes women to an increased risk of both physical and mental morbidities, which
   may also impair sexual function. <sup>12,28</sup> Women with POI have been described to have impaired sexual function
- may also impair sexual function.  $^{12,28}$  Women with POI have been described to have impaired sexual functio in their 40s, compared to premenopausal women at the same age  $^{11}$ , and even compared to peri- and
- in their 40s, compared to premenopausal women at the same age <sup>11</sup>, and even compared to peri- and
   postmenopausal women aged 45-65 <sup>8</sup>. To the best of our knowledge, only a few studies have evaluated the
- 240 positionopausal women aged 45-05 . To the best of our knowledge241 effect of early menopause on sexual function.
- In addition to more advanced menopausal status, weaker self-reported general health was associated with 242 impaired sexual function in this study. Many physical and mental diseases as well as medications may affect 243 sexual function<sup>29</sup>. As both the symptoms of the disease and the medications may increase the risk of 244 245 impaired sexual function, we suggest that a participant's own experience of her general health is a representative marker of wellbeing. Living with a partner was negatively associated with several domains of 246 247 sexual function, which we believe reflects the fact that having a relationship may make sexuality-related 248 problems more prominent. Higher FAI levels were associated with better sexual function. Previous studies 249 have consistently shown that FAI is inversely associated with sexual dysfunction in both premenopausal and postmenopausal women 17-19. 250
- Of all the investigated sexuality-related variables, climacteric women had the highest odds ratio for having more frequent and distressing vaginal dryness. In a study by Cagnacci et al., vaginal dryness was independently correlated with several other domains of sexual function: desire, arousal, lubrication, orgasm, satisfaction, and dyspareunia <sup>30</sup>. Vaginal dryness is a common symptom that becomes more prevalent with advancing menopausal stage. A longitudinal Australian study of women aged 45-55 years, followed for seven years, reported that the prevalence of vaginal dryness was 4% in early perimenopause, 25% one year
- after last menstrual period, and 47% three years after last menstrual period <sup>31</sup>. A study of postmenopausal
  women by Kingsberg et al. reported that enjoyment of sex was negatively affected by vulvovaginal atrophy
  in 59% of the participants <sup>32</sup>. Local estrogen and estrogen-androgen therapies are very effective in improving
  sexual function in postmenopausal women suffering from urogenital atrophy <sup>33</sup>; non-hormonal local
  preparations such as lubricant and moisturizers also significantly relieve the symptoms of vulvovaginal
  atrophy <sup>34</sup>. Lack of knowledge of the treatment options and unwillingness to broach the topic of vaginal
- 263 complaints with health care professionals, may prevent many women from receiving optimal treatment for 264 vaginal dryness  $^{32}$ .
- It has been reported that sexual dysfunction is very frequent in women attending menopause clinics; however, only a small proportion of women visiting gynecologists report sexual complaints spontaneously. <sup>35</sup>. Hence, it is important that clinicians ask about patients' sexual concerns. As in our analysis, living with a partner was associated with impaired sexual function; therefore, therapeutic methods for couples might be helpful for women concerned about their partnered sex life.
- 270 In the subanalysis of our study on climacteric women only, having more disturbing hot flashes and having 271 purchased HT during the past year were associated with impaired sexual function. HT is effective in treating hot flashes <sup>36</sup>, and it seems to have a small-to-moderate benefit in sexual function for women who have 272 menopausal symptoms and/or are in early postmenopause, but not in unselected postmenopausal women <sup>6</sup>. 273 274 Moreover, evidence suggests that transdermal HT may improve sexual function while oral HT seems to have no effect <sup>37</sup>. As the number of HT users in our study population was small and the details of the use (dose, 275 duration of use, administration route, continuity, effectiveness on the menopausal symptoms) variable, 276 277 further conclusions cannot be drawn. It is likely that women who purchase HT have been suffering from 278 more prominent menopausal symptoms.

- 279 Our study has several strengths. This was a population-based birth cohort study that comprehensively
- evaluated lifestyle and health issues. The participants were not recruited from menopausal clinics; thus the
- findings reflect the situation in the general population. There is also evidence that several domains of sexual
- function in middle-aged women are affected by age <sup>30,38</sup> and ethnicity <sup>39</sup>. The women in this study population
- were born within approximately one year. The ethnicity of the women was highly homogenous. The
- questions evaluating sexual function were easy to understand and answer. We evaluated not only the
   frequency of vaginal dryness and low sexual desire, but also how disturbing the women found these
- symptoms, as we found this to be an important point of view in screening and treating sexual dysfunction. As
- the NFBC1966 data collection has been comprehensive, including linking to nationwide register data,
- versatile essential covariates were included into the regression models.
- 289 The weaknesses of this study include its cross-sectionality, as with many other studies evaluating sexual 290 wellbeing. This study did not include validated questionnaires for measuring sexual function. Additionally, data on the duration of sexual dysfunction were not available. Sexual function is affected by several physical, 291 292 mental, social, and environmental factors; hence it may vary significantly during even a short period of time. Furthermore, the participants' gender identity and sexual orientation were not evaluated in this study. Owing 293 294 to the homogenous ethnicity and cultural background of the study subjects, it is unclear whether the study 295 findings can be applied to other populations. Despite some drawbacks, we were able to comprehensively 296 investigate sexual function in relation to menopausal status in middle-aged women who were several years 297 younger than the average age at menopause.
- 298

## 299 Conclusion

In conclusion, the risk of impaired sexual function was increased in women who were in late perimenopause 300 301 or postmenopause at the age of 46, compared to premenopausal women at the same age. In addition, this 302 study showed that self-experienced health was strongly associated with sexual function. In health care, 303 women facing menopausal transition at an early age should be asked about their sexuality-related concerns and counselled about possible solutions for improving their sex life. Health care professionals can help 304 305 improve the sexual function of these women by opening the conversation about sexuality-related issues and offering adequate information about the multifactorial background and possible treatments of sexual 306 307 dysfunction around menopause.

308

# 309 Acknowledgements

- 310 This work was supported by the Northern Ostrobothnia Hospital District, Oulu University Hospital, the
- 311 University of Oulu, the Finnish Menopause Society, Juho Vainio Foundation, and the Finnish Medical
- Foundation. We thank all cohort members and researchers who participated in the 46-year study. We also
- 313 wish to acknowledge the work of the NFBC project center.
- 314

#### 315 **References**

- 316
- Scavello I, Maseroli E, Di Stasi V, Vignozzi L. Sexual Health in Menopause. *Medicina* (*Kaunas*)2019;55(9):559. doi:10.3390/medicina55090559
- Goldstein I, Traish A, Kim N, Munarriz R. The role of sex steroid hormones in female sexual function and dysfunction. *Clin Obstet Gynecol* 2004;47(2):471-484. doi:10.1097/00003081-200406000-00022

- Burger HG, Hale GE, Robertson DM, Dennerstein L. A review of hormonal changes during the
   menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. *Hum Reprod Update* 2007;13(6):559-565. doi:10.1093/humupd/dmm020
- Avis NE, Zhao X, Johannes CB, Ory M, Brockwell S, Greendale GA. Correlates of sexual function
  among multi-ethnic middle-aged women: results from the Study of Women's Health Across the
  Nation (SWAN). *Menopause* 2018;25(11):1244-1255. doi:10.1097/GME.00000000001226
- Nazarpour S, Simbar M, Tehrani FR, Majd HA. The relationship between menopausal symptoms and sexual function. *Women Health* 2018;58(10):1112-1123. doi:10.1080/03630242.2017.1414100
- Nastri CO, Lara LA, Ferriani RA, Rosa-E-Silva ACJS, Figueiredo JBP, Martins WP. Hormone
   therapy for sexual function in perimenopausal and postmenopausal women. *Cochrane Database Syst Rev* 2013;(6):CD009672. doi:10.1002/14651858.CD009672.pub2
- Mishra GD, Pandeya N, Dobson AJ, et al. Early menarche, nulliparity and the risk for premature and early natural menopause. *Hum Reprod* 2017;32(3):679-686. doi:10.1093/humrep/dew350
- Mann E, Singer D, Pitkin J, Panay N, Hunter MS. Psychosocial adjustment in women with premature menopause: A cross-sectional survey. *Climacteric* 2012;15(5):481-489.
   doi:10.3109/13697137.2011.647841
- 338 9. Kalantaridou SN, Vanderhoof VH, Calis KA, Corrigan EC, Troendle JF, Nelson LM. Sexual function
  in young women with spontaneous 46,XX primary ovarian insufficiency. *Fertil Steril*2008;90(5):1805-1811. doi:10.1016/j.fertnstert.2007.08.040
- 10. Van Der Stege JG, Groen H, Van Zadelhoff SJN, et al. Decreased androgen concentrations and
   diminished general and sexual well-being in women with premature ovarian failure. *Menopause* 2008;15(1):23-31. doi:10.1097/gme.0b013e3180f6108c
- de Almeida DMB, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian
   failure. *Menopause* 2011;18(3):262-266. doi:10.1097/gme.0b013e3181f4318d
- Nappi RE, Cucinella L, Martini E, et al. Sexuality in premature ovarian insufficiency. *Climacteric* 2019;22(3):289-295. doi:10.1080/13697137.2019.1575356
- 348 13. Deeks AA, Gibson-Helm M, Teede H, Vincent A. Premature menopause: A comprehensive understanding of psychosocial aspects. *Climacteric* 2011;14(5):565-572.
  350 doi:10.3109/13697137.2011.566390
- 351 14. Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. *Climacteric* 2019;22(4):403-411.
  353 doi:10.1080/13697137.2019.1574738
- 15. Choi J, Shin DW, Lee S, et al. Dose-response relationship between cigarette smoking and female
   sexual dysfunction. *Obstet Gynecol Sci* 2015;58(4):302-308. doi:10.5468/ogs.2015.58.4.302
- Ju R, Ruan X, Xu X, et al. Importance of active and passive smoking as one of the risk factors for female sexual dysfunction in Chinese women. *Gynecol Endocrinol* 2021;37(6):541-545.
   doi:10.1080/09513590.2021.1913115
- Vale FBC, Coimbra BB, Lopes GP, Geber S. Sexual dysfunction in premenopausal women could be related to hormonal profile. *Gynecol Endocrinol* 2017;33(2):145-147.
  doi:10.1080/09513590.2016.1226793
- Turna B, Apaydin E, Semerci B, Altay B, Cikili N, Nazli O. Women with low libido: correlation of decreased androgen levels with female sexual function index. *Int J Impot Res* 2005;17(2):148-153.
  doi:10.1038/sj.ijir.3901294
- Wåhlin-Jacobsen S, Kristensen E, Pedersen AT, et al. Androgens and Psychosocial Factors Related to
   Sexual Dysfunctions in Premenopausal Women(\*): (\*)2016 ISSM Female Sexual Dysfunction Prize.

- 367 *J Sex Med* 2017;14(3):366-379. doi:10.1016/j.jsxm.2016.12.237
- 20. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors.
   *JAMA* 1999;281(6):537-544. doi:10.1001/jama.281.6.537
- Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. *J Sex Med* 2004;1(1):35-39. doi:10.1111/j.1743-6109.2004.10106.x
- 372 22. University of Oulu: Northern Finland Birth Cohort 1966. University of Oulu.
  373 https://www.oulu.fi/nfbc/node/44315.
- 374 23. Nordström T, Miettunen J, Auvinen J, et al. Cohort Profile: 46 years of follow-up of the Northern
  375 Finland Birth Cohort 1966 (NFBC1966). *Int J Epidemiol* 2022;50(6):1786-1787j.
  376 doi:10.1093/ije/dyab109
- Bui HN, Sluss PM, Hayes FJ, et al. Testosterone, free testosterone, and free androgen index in
  women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. *Clin Chim Acta* 2015;450:227-232. doi:10.1016/j.cca.2015.08.019
- Harlow SD, Gass M, Hall JE, et al. Executive summary of the stages of reproductive aging workshop
   + 10: Addressing the unfinished agenda of staging reproductive aging. *J Clin Endocrinol Metab* 2012;97(4):1159-1168. doi:10.1210/jc.2011-3362
- Buczak-Stec E, König HH, Hajek A. The link between sexual satisfaction and subjective well-being:
  a longitudinal perspective based on the German Ageing Survey. *Qual Life Res* 2019;28(11):30253035. doi:10.1007/s11136-019-02235-4
- Woloski-Wruble AC, Oliel Y, Leefsma M, Hochner-Celnikier D. Sexual activities, sexual and life
  satisfaction, and successful aging in women. *J Sex Med* 2010;7(7):2401-2410. doi:10.1111/j.1743-6109.2010.01747.x
- Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. *Climacteric* 2015;18(4):483–491.
  doi:10.3109/13697137.2015.1020484
- McCabe MP, Sharlip ID, Lewis R, et al. Risk Factors for Sexual Dysfunction Among Women and
   Men: A Consensus Statement From the Fourth International Consultation on Sexual Medicine 2015. J
   Sex Med 2016;13(2):153-167. doi:10.1016/j.jsxm.2015.12.015
- 395 30. Cagnacci A, Venier M, Xholli A, Paglietti C, Caruso S. Female sexuality and vaginal health across
  396 the menopausal age. *Menopause* 2020;27(1):14-19. doi:10.1097/GME.00000000001427
- 397 31. Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study
   398 of menopausal symptoms. *Obstet Gynecol* 2000;96(3):351-358. doi:10.1097/00006250-200009000 399 00007
- 400 32. Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal
  401 women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal
  402 Vaginal ChangEs) survey. J Sex Med 2013;10(7):1790-1799. doi:10.1111/jsm.12190
- 33. Raghunandan C, Agrawal S, Dubey P, Choudhury M, Jain A. A comparative study of the effects of
  local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in
  postmenopausal women. J Sex Med 2010;7(3):1284-1290. doi:10.1111/j.1743-6109.2009.01667.x
- 406 34. Potter N, Panay N. Vaginal lubricants and moisturizers: a review into use, efficacy, and safety.
   407 *Climacteric* 2021;24(1):19-24. doi:10.1080/13697137.2020.1820478
- 40835.Cuerva MJ, Gonzalez D, Canals M, et al. The sexual health approach in postmenopause: The five-409minutes study. *Maturitas* 2018;108:31-36. doi:10.1016/j.maturitas.2017.11.009
- 410 36. Kaunitz AM, Manson JE. Management of Menopausal Symptoms. Obstet Gynecol 2015;126(4):859-

- 411 876. doi:10.1097/AOG.000000000001058
- 412 37. Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in
  413 early postmenopause: Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS).
  414 JAMA Intern Med 2017;177(10):1471-1479. doi:10.1001/jamainternmed.2017.3877
- 415 38. Chedraui P, Perez-Lopez FR, San Miguel G, Avila C. Assessment of sexuality among middle-aged
  416 women using the Female Sexual Function Index. *Climacteric* 2009;12(3):213-221.
  417 doi:10.1080/13697130802607727
- 418 39. Huang AJ, Subak LL, Thom DH, et al. Sexual function and aging in racially and ethnically diverse
  419 women. *J Am Geriatr Soc* 2009;57(8):1362-1368. doi:10.1111/j.1532-5415.2009.02353.x
- 420

## 421 Figure and Table legends

- 422 **FIG 1:** Flow chart of the study population.
- 423 The study participants were members of the prospective Northern Finland Birth Cohort 1966 (NFBC1966),
- 424 who participated in a 46-year follow-up study of NFBC1966. FSH, follicle stimulating hormone; HT,
- 425 systemic hormone therapy with estrogen; CHC, combined hormonal contraception. \*The women receiving
- 426 progestin-only treatment or who were hysterectomized were classified according to their FSH levels.
- 427 **TABLE 1**. Background characteristics of the study participants.
- 428 The study participants were women of the Northern Finland Birth Cohort 1966, who attended a 46-year
- follow-up study of the cohort and were divided into two groups according to their climacteric status at the
- 430 age of 46 years. Distributions of categorical variables were compared using Pearson's  $\chi^2$  test. Continuous
- 431 variables were compared using independent samples t-test<sup>(a)</sup> or Mann-Whitney U test<sup>(b)</sup>. BMI, body mass
- 432 index; SD, standard deviation; IQR, interquartile range; FAI, free androgen index.
- **TABLE 2**. Climacteric status at the age of 46 and variables evaluating sexual desire and vaginal dryness.
- 434 The study participants were women of the Northern Finland Birth Cohort 1966, who attended a 46-year
- follow-up study of the cohor and were divided into two groups according to their climacteric status at the age
- 436 of 46 years. The analyses were performed with Pearson's  $\chi^2$  test. <sup>a</sup> The women who reported not having a
- 437 partner were excluded from the analysis.
- **FIG 2.** Forest plot of climacteric status and sexual dysfunction at the age of 46.
- 439 The forest plot presents the results (odds ratios with 95% confidence intervals) from binary logistic
- regression models, in which climacteric status, self-reported health, free androgen index (FAI), smoking,
- 441 living with a partner or not, and level of education were independent variables. Level of education was not
- 442 associated with any of the variables and is not shown in the figure.
- Table 3. Climacteric status and sexual dysfunction at the age of 46, the unadjusted and adjusted results (the
  odds ratios with 95% confidence intervals) from binary logistic regression models.
- 445

The study participants were women of the Northern Finland Birth Cohort 1966, who attended a 46-year
follow-up study of the cohort and were divided into two groups according to their climacteric status at the

448 age of 46 years. The table shows the odds rations with 95% confidence intervals from unadjusted (<sup>a</sup>) and

- adjusted (<sup>b</sup>) binary logistic regression models. The independent variables in the adjusted models were
- 450 climacteric status, self-reported health, free androgen index (FAI), smoking, living with a partner or not, and
- 451 level of education were independent variables. Level of education was not associated with any of the
- variables and is not shown in the table. <sup>c</sup>Scale 1 (not at all) to 7 (very much); <sup>d</sup>continuous variable; FAI, free
- 453 androgen index.454


Table 1


Variable	Climacteric (n=359)	Preclimacteric (n=2302)	<i>P</i> -value	
BMI (mean, SD) <sup>a</sup>	26.3 (5.2)	26.6 (5.3)	0.408	
Level of education (n,%)	20.5 (5.2)	20.0 (5.5)	0.040	
Basic	26 (7.3)	112 (5.0)		
Secondary	236 (66.7)	1424 (63.7)		
Tertiary	92 (26.0)	701 (31.3)		
Smoking (n,%)			0.003	
No	266 (76.9)	1849 (83.3)		
Yes	80 (23.1)	370 (16.7)		
Self-reported general			0.230	
health (n,%)				
Good-very good	232 (66.3)	1539 (69.5)		
Moderate-poor	118 (33.7)	676 (30.5)		
Disturbance from hot			< 0.001	
flashes (Scale 1 (not at				
all)-7 (very much) (n, %)				
1–2	227 (64.5)	1973 (89.1)		
3–7	125 (35.5)	241 (10.9)		
Alcohol intake	3.0 (7.1)	2.9 (7.2)	0.506	
(grams/day) (median, IQR) <sup>b</sup>				
FAI (median, IQR) <sup>b</sup>	1.5 (1.2)	1.6 (1.1)	0.313	
Marital status (n, %)			0.734	
Married/domestic	284 (80.2)	1742 (78.0)		
partnership	~ /			
Unmarried	34 (9.6)	219 (9.8)		
Divorced	34 (9.6)	259 (11.6)		
Widow	2 (0.6)	12 (0.5)		

Tabl	le 2

Variables of sexual desire and vaginal dryness	Climacteric (n=359) n(%)	Preclimacteric (n=2302) n(%)	<i>P</i> -value
How often do you suffer from low desire for sex?			< 0.001
Not at all or rarely	245 (70.2)	1958 (87.9)	
Sometimes, quite often, or very often	104 (29.8)	270 (12.1)	
How often do you suffer from vaginal dryness?			< 0.001
Not at all or rarely	261 (74.8)	2054 (92.1)	
Sometimes, quite often, or very often	88 (25.2)	175 (7.9)	
How much difficulty do you experience as a result			< 0.001
of a low desire for sex? (Scale 1 (not at all)–7 (very much)			
1–2	242 (69.3)	1960 (88.8)	
3–7	107 (30.7)	248 (11.2)	
How much difficulty do you experience as a result of vaginal dryness? (Scale 1 (not at all)–7 (very much)			< 0.001
1–2	262 (75.3)	2041 (92.3)	
3–7	86 (24.7)	171 (7.7)	
How often do you think about sex?	00(2)		0.019
Once a month or less	96 (27.6)	482 (21.9)	
At least once a week	252 (72.4)	1719 (78.1)	
How often do you have sexual			0.806
intercourse/masturbate			
Often than once a month or less	99 (28.9)	618 (28.2)	
At least once a week	244 (71.1)	1572 (71.8)	
Do you have problems with sexual intercourse at	~ /	× /	< 0.001
the moment? <sup>a</sup>			
No	292 (90.4)	1936 (95.6)	
Yes	31 (9.6)	89 (4.4)	

	Being climacteric <sup>a</sup> OR (95% CI)	Being climacteric <sup>b</sup> OR (95% CI)	FAI <sup>b,d</sup> OR (95% CI)	Being a smoker <sup>b</sup> OR (95% CI)	Living with partner <sup>b</sup> OR (95% CI)	Weaker general health (moderate– very week compared to good– very good) <sup>b</sup> OR (95% CI)
Higher frequency of low sexual	2.00 (2.27	0.00 (0.10	0.05 (0.76		1.02 (1.40	1 07 (1 55
desire (sometimes, quite often or very often compared to not at all	3.08 (2.37–	2.80 (2.12– 3.71	0.85 (0.76–	1.00 (0.70, 1.46)	1.93 (1.40–	1.97 (1.55–
to rarely)	4.00)	3./1	0.97)	1.08 (0.79–1.46)	2.67)	2.51)
Higher frequency of vaginal						
dryness (sometimes, quite often	3.96 (2.97–	3.83 (2.82–	0.83 (0.71–	0.64 (0.43–		
or very often compared to not at	5.27)	5.20)	0.96)	0.95)	1.72 (1.18–2.52)	1.83 (1.38–2.43)
all to rarely)	3.27)	0.20)	0.20)	0.95)	1.72 (1.10 2.52)	
Experiencing more difficulty as a						
result of low sexual desire in	3.49 (2.69–	3.22 (2.43–				
scale 1 to 7 <sup>c</sup>	4.55)	4.27)	0.89 (0.79-1.01)	1.12 (0.82–1.53)	2.44 (1.71-3.50)	1.96 (1.52–2.51)
(3–7 compared to 1–2)						
Experiencing more difficulty as a						
result of vaginal dryness in scale	3.92 (2.93–	3.75 (2.75–				
1 to 7 <sup>c</sup>	5.23)	5.12)	0.88 (0.76–1.02)	0,68 (0.46–1.01)	2,41 (1.58–3.70)	2.07 (1.56-2.75)
(3–7 compared to 1–2)						
Thinking about sex less often						
(not more than once a month	1.36 (1.05–	1.34 (1.02–				
compared to at least once a week)	1.76)	1.75)	0.82(0.74–0.91)	1.08 (0.84–1.39)	0.81 (0.65–1.02)	1.44 (1.18–1.77)
Having intercourse/masturbating	1.03 (0.80–	1.08 (0.83–				
less frequently (not more than	1.33)	1.41)	0.89 (0.81–0.98)	1,09 (0.86–1.38)	0.50 (0.40-0.61)	1.44 (1.18–1.74)
once a month compared to at	/		(	, (		
least once a week)						
Having problems with sexual	2.31 (1.51–	2.35 (1.51-				
intercourse (yes compared to no)	3.54)	3.66)	0.72 (0.58-0.90)	1.29 (0.81–2.08)	2,05 (1.05-4.00)	2.52 (1.71-3.70)
excluding women having no partner			. ,	. ,		. ,





5 6

Figure 2